SG/CALL/NOVO-NORDISK B/1150/0.1/19.06.26 | Market Closed - Boerse Frankfurt Warrants 03:42:04 2024-07-12 pm EDT | ||
| 2.16 EUR | +4.35% |
|
| Current month | -5.63% | ||
| 1 month | -8.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 2.18 | +5.31% |
| 24-07-11 | 2.07 | -5.91% |
| 24-07-10 | 2.2 | +2.33% |
| 24-07-09 | 2.15 | -5.29% |
| 24-07-08 | 2.27 | +2.25% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 03:42 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CV6 |
| ISIN | DE000SU9CV64 |
| Date issued | 2024-02-14 |
| Strike | 1,150 kr |
| Maturity | 2026-06-19 (706 Days) |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.55 € |
|---|---|
| Lowest since issue | 1.55 € |
| Spread | 0.04 € |
| Spread % | 1.83% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
- Stock Market
- Warrants
- Warrant
